Sivik Global Healthcare LLC Has $5.74 Million Holdings in Danaher Co. (NYSE:DHR)

Sivik Global Healthcare LLC lessened its stake in shares of Danaher Co. (NYSE:DHR) by 16.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,000 shares of the conglomerate’s stock after selling 5,000 shares during the quarter. Danaher comprises 3.0% of Sivik Global Healthcare LLC’s investment portfolio, making the stock its 12th biggest holding. Sivik Global Healthcare LLC’s holdings in Danaher were worth $5,739,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently bought and sold shares of the business. Wedge Capital Management L L P NC grew its stake in Danaher by 3.2% in the 3rd quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after purchasing an additional 38 shares during the period. Meridian Financial Partners LLC lifted its position in shares of Danaher by 4.4% during the third quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock worth $266,000 after acquiring an additional 40 shares in the last quarter. Kovack Advisors Inc. grew its position in shares of Danaher by 3.4% in the third quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock valued at $346,000 after purchasing an additional 41 shares in the last quarter. Well Done LLC lifted its holdings in Danaher by 1.2% during the 3rd quarter. Well Done LLC now owns 3,551 shares of the conglomerate’s stock worth $987,000 after purchasing an additional 42 shares in the last quarter. Finally, Waypoint Capital Advisors LLC grew its holdings in Danaher by 0.9% during the 3rd quarter. Waypoint Capital Advisors LLC now owns 4,520 shares of the conglomerate’s stock valued at $1,257,000 after buying an additional 42 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Trading Up 0.6 %

Shares of NYSE DHR opened at $224.96 on Thursday. Danaher Co. has a fifty-two week low of $223.00 and a fifty-two week high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The company has a market cap of $162.48 billion, a price-to-earnings ratio of 43.02, a PEG ratio of 4.43 and a beta of 0.83. The business’s 50 day moving average price is $236.09 and its 200-day moving average price is $253.66.

Danaher (NYSE:DHR) last issued its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. During the same quarter last year, the company earned $2.09 earnings per share. On average, sell-side analysts expect that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.48%. The ex-dividend date is Friday, December 27th. Danaher’s payout ratio is 20.61%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on DHR shares. Bank of America upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective for the company in a research report on Friday, December 13th. TD Cowen upped their price objective on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Jefferies Financial Group lowered their price objective on shares of Danaher from $285.00 to $260.00 and set a “buy” rating on the stock in a research report on Wednesday. Scotiabank assumed coverage on Danaher in a report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price objective for the company. Finally, Royal Bank of Canada cut their target price on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $280.57.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.